Pyruvate protects against experimental stroke via an anti-inflammatory mechanism

  • Wang Q
  • van Hoecke M
  • Tang X
 et al. 
  • 24


    Mendeley users who have this article in their library.
  • 47


    Citations of this article.


Pyruvate, a key intermediate in glucose metabolism, was explored as a potential treatment in models of experimental stroke and inflammation. Pyruvate was administered to rodents after the onset of middle cerebral artery occlusion (MCAO). Since the extent of inflammation is often proportional to the size of the infarct, we also studied a group of animals given lipopolysaccharide (LPS) to cause brain inflammation without cell death. Following MCAO, pyruvate did not affect physiological parameters but significantly reduced infarct volume, improved behavioral tests and reduced numbers of neutrophils, microglial and NFκB activation. Animals given LPS showed increased microglial and NFκB activation which was almost completely abolished by pyruvate. Lactate, a major metabolite of pyruvate, was increased after pyruvate administration. However, administration of lactate itself did not have any anti-inflammatory effects. Pyruvate protects against ischemia possibly by blocking inflammation, but lactate itself does not appear to explain pyruvate's anti-inflammatory properties.

Author-supplied keywords

  • Cerebral ischemia
  • Inflammation
  • Neuroprotection
  • Pyruvate
  • Stroke

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Qing Wang

  • Michael van Hoecke

  • Xian Nan Tang

  • Hokyou Lee

  • Zheng Zheng

  • Raymond A. Swanson

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free